Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Anatol J Cardiol ; 22(5): 240-249, 2019 11.
Article in English | MEDLINE | ID: mdl-31674929

ABSTRACT

OBJECTIVE: Endocan, chemerin, and galectin-3 are discrete biomarkers associated with cardiovascular diseases and acting through different pathophysiological pathways. The aim of this study is to investigate and compare the effects of high doses of atorvastatin and rosuvastatin on serum endocan, chemerin, and galectin-3 levels in patients with acute myocardial infarction (AMI). METHODS: Sixty-three patients with AMI were randomized to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) after percutaneous revascularization. Serum levels of endocan, chemerin, and galectin-3 were evaluated at baseline and after 4-week therapy. RESULTS: Endocan levels were not decreased statistically significantly with atorvastatin 80 mg, but rosuvastatin 40 mg markedly decreased the levels of endocan according to baseline [from 110.27 (86.03-143.69) pg/mL to 99.22 (78.30-122.87) pg/mL with atorvastatin 80 mg and from 110.73 (77.28-165.22) pg/mL to 93.40 (70.48-115.13) pg/mL with rosuvastatin 40 mg, p=0.242 for atorvastatin 80 mg and p=0.014 for rosuvastatin 40 mg]. Chemerin levels significantly decreased in both groups according to baseline [from 264.90 (196.00-525.95) ng/mL to 135.00 (105.95-225.65) ng/mL with atorvastatin 80 mg and from 309.95 (168.87-701.27) ng/mL to 121.25 (86.60-212.65) ng/mL with rosuvastatin 40 mg, p<0.001, respectively, for both groups]. Galectin-3 levels did not change markedly with atorvastatin 80 mg, but they decreased with rosuvastatin 40 mg [from 17.00 (13.10-22.25) ng/mL to 19.30 (15.25-23.45) ng/mL with atorvastatin 80 mg, p=0.721, and from 18.25 (12.82-23.82) ng/mL to 16.60 (10.60-20.15) ng/mL with rosuvastatin 40 mg, p=0.074]. There were no significant between-group differences in terms of absolute and percentage changes of endocan, chemerin, and galectin-3 at 4 weeks. CONCLUSION: We reported that both statins similarly decreased the endocan levels, whereas rosuvastatin seems to have more prominent effects on the reduction of the chemerin and galectin-3 levels in patients with AMI.


Subject(s)
Atorvastatin/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Myocardial Infarction/blood , Rosuvastatin Calcium/pharmacology , Angioplasty , Biomarkers/blood , Blood Proteins , Chemokines/blood , Chemokines/drug effects , Female , Galectin 3/blood , Galectin 3/drug effects , Galectins , Humans , Male , Middle Aged , Myocardial Infarction/therapy , Neoplasm Proteins/blood , Neoplasm Proteins/drug effects , Proteoglycans/blood , Proteoglycans/drug effects , Treatment Outcome
2.
Clin Exp Rheumatol ; 32(4 Suppl 84): S106-8, 2014.
Article in English | MEDLINE | ID: mdl-25005759

ABSTRACT

Behçet's disesase is a vasculitis that manifests with oral and genital ulcerations, skin lesions, uveitis, vascular, central nervous system and gastrointestinal involvement. While most patients develop mucocutaneous and genital ulcers along with eye disease, other patients may also present with arthritis, frank vasculitis, thrombophlebitis and central nervous system disease. This is the first case in the literature, where the diagnosis of Behçet's disease was made secondary to concomitant involvement of coronary and carotid arteries.


Subject(s)
Behcet Syndrome/complications , Behcet Syndrome/diagnostic imaging , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/etiology , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/etiology , Adolescent , Behcet Syndrome/pathology , Carotid Artery Diseases/pathology , Coronary Artery Disease/pathology , Delayed Diagnosis , Humans , Magnetic Resonance Imaging , Male , Tomography, X-Ray Computed
4.
Auton Neurosci ; 167(1-2): 70-4, 2012 Apr 03.
Article in English | MEDLINE | ID: mdl-22104493

ABSTRACT

BACKGROUND: Familial Mediterranean fever (FMF) is characterized by sporadic, acute attacks of fever and serositis. Cardiovascular involvement is one of the leading cause of morbidity and mortality among FMF patients. Herein, we aimed to evaluate cardiac autonomic functions in FMF patients without overt cardiac symptoms. METHODS: We enrolled 38 patients (20 female; mean age 34.4 ± 10.2 years) with FMF and 34 healthy subjects (18 female; mean age 33.2 ± 9.3 years). All participants underwent 24-hour Holter recording. Heart rate recovery (HRR) indices were calculated by subtracting first, second, and third minute heart rates from maximal heart rate. All patients underwent heart rate variability (HRV), heart rate turbulance (HRT) and QT dispersion analysis. The mean FMF duration was 9.8 ± 4.2 years. RESULTS: Both groups were similar with regard to baseline characteristics. Mean HRR1 (p=0.001), HRR2 (p=0.003) and HRR3 (p<0.001) were significantly lower in FMF group. SDNN (standard deviation of all NN intervals), SDANN (SD of the 5 min mean RR intervals), RMSSD (root square of successive differences in RR interval), and PNN50 (proportion of differences in successive NN intervals >50 ms) and high-frequency (HF) components were significantly decreased, but low frequency (LF) and LF/HF were significantly higher in FMF patients. HRT onset and slope were significantly less negative in FMF patients. Also, QTd was significantly higher in FMF patients (p<0.001). CONCLUSION: Patients with FMF showed delayed recovery of heart rate and abnormal HRV and HRT parameters with respect to normal subjects. Cardiac autonomic functions might be involved in FMF patients even in patients without cardiac symptoms.


Subject(s)
Autonomic Nervous System/physiopathology , Colchicine/therapeutic use , Familial Mediterranean Fever/drug therapy , Familial Mediterranean Fever/physiopathology , Heart/innervation , Heart/physiopathology , Adult , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/physiopathology , Blood Sedimentation , Body Mass Index , Echocardiography , Electrocardiography , Exercise Test , Female , Heart Function Tests , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...